Denali Therapeutics Inc. 8-K

What Happened

• Denali Therapeutics Inc. announced on January 6, 2026 (via an 8-K) that it issued a press release providing an update on its programs and expected milestones for 2026 and confirming the company’s participation in the 44th Annual J.P. Morgan Healthcare Conference. The press release is furnished as Exhibit 99.1 to the filing and the disclosure was made under Regulation FD.

Key Details

• Date of disclosure: January 6, 2026.
• Content: program updates and expected milestones for 2026 (details provided in the attached press release).
• Event participation: 44th Annual J.P. Morgan Healthcare Conference.
• Exhibit: press release attached as Exhibit 99.1 (Item 9.01 notes the exhibit is furnished and not “filed” for Section 18 liability or automatically incorporated by reference).

Why It Matters

• Program updates and milestone timelines are potential near-term catalysts investors watch for biotech companies; the press release and any JPMorgan presentation may clarify development timelines and upcoming data or regulatory milestones.
• Participation in the J.P. Morgan Healthcare Conference signals management will engage with investors and analysts, which can provide additional detail or color beyond the press release.
• The filing does not report earnings, revenue, quarterly results, executive changes (CEO/CFO), mergers, acquisitions, or other financial statements. Investors should review the attached press release (Exhibit 99.1) and any JPMorgan presentation for substantive program or timeline specifics.